Grant Life Sciences has secured rights to technology for rapid testing of AIDS and Dengue Fever, the company said Monday.

GLS licensed the technology from AccuDx Corp. The platform is for use at points of care.

GLS said it also gained rights to a colloidal gold reagent that is used as part of other rapid tests.

The deal includes the rights for GLS to manufacture the products at an AccuDx facility in Tijuana, Mexico.

“We expect this agreement will allow us to generate early revenues in specialty diagnostic markets from established channels of distribution in India, Southeast Asia and the Middle East,” said Stan Yakatan, chief executive officer of GLS.

Grant Life Sciences: